- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| So | Gilead CEO Dan O'Day offers a detailed explanation on remdesivir access - reassuring analysts that Covid-19 data are coming fast | ||
| Fr | As share buybacks come under scrutiny, what's in store for the biopharma industry? | ||
| Fr | A Singapore VC raises $200M for a new round, but will Covid-19 prevent it from raising the rest? | ||
| Fr | Struggling Unum execs are ready to consider a sale, merger or any deal that comes its way | ||
| Fr | FDA ends CSR pilot, plots new approach for disclosing study reports | ||
| Fr | Jim Robinson takes over the reins at Urovant; Carlos Campoy moves to CytomX | ||
| Fr | VBL and its "gene therapy" cancer treatment are back - with a peek at PhIII potential | ||
| Fr | UPDATED: Covid-19 roundup: British PM Johnson tests positive for coronavirus; More companies join hunt for Covid-19 vaccine | ||
| Fr | Sanofi turns to an upstart in the mRNA field in latest attempt to quickly squelch a global pandemic | ||
| Do | Pfizer hits the brakes on (most) trial recruitment - but they're circling the wagons around top priorities | ||
| Do | Pfizer, Mylan deal takes a coronavirus hit | ||
| Do | Takeda antes up $44M for rare disease pact, turning to Oxford spinout's exosome tech | ||
| Do | EMA offers methodological considerations for trials during Covid-19 pandemic | ||
| Do | Kept on hold at the FDA, Ipsen scraps a key trial and revamps R&D path for its troubled $1B-plus rare disease drug | ||
| Do | Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world | ||
| Do | SutroVax lands another $100M+ in upstart quest against Pfizer's blockbuster Prevnar 13 | ||
| Do | Covid-19 roundup: Biopharma industry teams up to spur defensive arsenal to fight pandemic; Regeneron relaxes Eylea payment terms | ||
| Do | Bristol Myers bags its 'blockbuster' FDA OK for ozanimod as a long and winding R&D road finally ends in the marketplace | ||
| Mi | After critics lambasted Gilead for grabbing the FDA's special rare drug status on remdesivir, they're giving it back | ||
| Mi | Roche forges deal with San Diego biotech, betting on new antibiotic class | ||
| Mi | Oprah day in biotech: Regenacy gets $30M, Abbisko gets $70M, Castle Creek gets $75M | ||
| Mi | Covid-19 roundup: Bristol Myers suspends clinical trials, grounds field team; Vir ushers antibody candidates to human testing | ||
| Mi | In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug | ||
| Mi | FDA issues another safety alert related to fecal transplants, as data suggest coronavirus lingers in poop | ||
| Mi | BeiGene scrambles to find new Abraxane supplier as Chinese inspectors order halt on imports, citing Bristol Myers failure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
